Treats alcohol dependence. ANDA 76264, held by Specgx LLC. Naltrexone Hydrochloride.
As of Nov 16, 2026, ANDA 76264 (Naltrexone Hydrochloride), held by Specgx LLC, was first approved by FDA on Mar 22, 2002, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. Naltrexone hydrochloride tablets have not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 22, 2002 | Original application | Approved |
| Naltrexone Hydrochloride25MG · tablet;oral | Naltrexone Hydrochloride | Rx |
| Naltrexone Hydrochloride50MG · tablet;oral | Naltrexone Hydrochloride | Rx |
| Naltrexone Hydrochloride100MG · tablet;oral | Naltrexone Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters